PVX-410 for smoldering multiple myeloma
What is PVX-410 for smoldering multiple myeloma?
PVX-410 is an experimental therapeutic cancer vaccine currently being developed to help slow or prevent the progression of smoldering multiple myeloma (SMM) into active multiple myeloma. The cancer vaccine is also being investigated as a possible treatment for triple-negative breast cancer.
SMM is an asymptomatic precancerous disorder in which abnormal plasma cells build up in the bone marrow, where blood cells are produced. Plasma cells are immune cells that produce antibodies. SMM can progress to multiple myeloma, a blood cancer in which cancerous plasma cells grow uncontrollably and crowd out healthy blood cells. This can damage tissues and cause a wide range of symptoms and complications.
Originally developed by Oncopep, PVX-410 is an investigational cancer vaccine designed to help the immune system recognize and attack abnormal plasma cells. The goal is to delay or prevent the progression of SMM into active multiple myeloma.
PVX-410 is given by injection under the skin. It is currently being tested in a Phase 1 clinical trial in combination with other therapies to treat SMM.
The investigational cancer vaccine has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of multiple myeloma. This designation supports the development of treatments for rare conditions.
Therapy snapshot
| Treatment name | PVX-410 |
| Administration | Subcutaneous injection |
| Clinical testing | Currently in Phase 1 testing |
How will PVX-410 be administered in SMM?
In clinical trials testing PVX-410 in people with SMM, the therapy has been given by injection under the skin every two weeks for about three months. PVX-410 has been given with other therapies, including a potent cancer vaccine adjuvant called Poly ICLC (Hiltonol), which helps boost patients’ immune responses to treatment.
The specific recommended dosage of PVX-410 for SMM has not yet been established.

PVX-410 in SMM clinical trials
Two early-phase clinical trials have assessed the safety and immune activity of PVX-410 in people with SMM:
- In the first Phase 1/2a trial (NCT01718899), patients received PVX-410 injections under the skin, either alone or with Revlimid (lenalidomide), an approved multiple myeloma treatment, for about three months. Patients were then followed for one year. Results showed that PVX-410 was generally well tolerated and triggered immune responses. These responses appeared stronger when the vaccine was combined with Revlimid.
- In the second Phase 1b trial (NCT02886065), patients received PVX-410 with citarinostat, an experimental targeted therapy for multiple myeloma and SMM, or PVX-410 with both citarinostat and Revlimid. The initial treatment period lasted about three months, and patients were followed for a total of 15 months. Results showed immune responses in both treatment groups, although it was unclear how much PVX-410 contributed to these responses. After 15 months of follow-up, only one of the 15 treated patients had progressed to active multiple myeloma. However, the researchers considered the clinical responses modest.
PVX-410 side effects
In Phase 1 studies of PVX-410, the cancer vaccine was generally well tolerated in people with SMM. Most reported side effects were mild to moderate.
The most common side effects reported in people receiving PVX-410 included:
- Injection-site reactions, including redness, swelling, pain, and discomfort at the injection site
- Fatigue
- Fever
- Chills
- Body aches
When PVX-410 is combined with other therapies, some side effects may occur more often or be more severe. Additional side effects may include:
- Reductions in blood cell counts
- Diarrhea
- Constipation
Rare Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.